GALT Chief Medical Officer Khurram Jamil Sells 2,533 Shares

Khurram Jamil Extends Recent Insider Activity at Galectin Therapeutics

Galectin Therapeutics Inc. (NasdaqCM: GALT) has seen active trading from top management. Chief Medical Officer Khurram Jamil was recently involved in stock transactions, adding to a string of filings from company leaders. This follows an acquisition of 4,570 shares on June 26, 2026, where shares were bought at an average price of $2.37 for a total value of $10,813.99.

More Insider Moves Shape GALT Trading

Management participation has picked up recently. On June 23, 2026, Khurram Jamil acquired 7,557 shares at a price of $1.23 per share, totaling $9,295.11. Shortly after, on June 26, 2026, another company insider, Harold Shlevin, picked up 7,732 shares at $1.23 each, representing a total value of $9,510.36. None of these reported transactions were marked as being part of a pre-arranged Rule 10b5-1 trading plan.

GALT Stock Context and Moving Averages

GALT shares recently changed hands at $4.64. The biotech equity maintains a position above both its 50-day moving average of $3.77 and its 200-day moving average of $3.36. Over the past year, the share price has seen lows near $2.03 and highs up to $7.13.

Analysts Set New Price Targets

Wall Street coverage remains sparse for the clinical-stage firm, but optimism persists among covering institutions. On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on the stock along with an $11.00 price target. The lone analyst opinion currently tracks that same $11 consensus target.

Inside Galectin Therapeutics Operations

Headquartered in Norcross, Georgia, Galectin Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer. Its primary candidate is belapectin, a galectin-3 inhibitor currently advancing through mid-stage clinical studies for liver fibrosis and cirrhosis conditions.

Looking Ahead for GALT

Investors are keeping an eye on upcoming operational milestones and financial updates from the firm. The company is slated to deliver its next financial report around August 11, 2025, providing further visibility into its cash burn and clinical trial progress.